Paul L. Berns, Director at Jazz Pharmaceuticals plc (JAZZ), sold 1,321 shares at $142.36 ($188K) on 2017-08-11, disclosed to the SEC on 2017-08-14.
Seasonal sale ($188k) by Director — this insider has traded JAZZ in August in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $142.36 | 659 | $94K | 49.9% |
| 2 | $142.36 | 659 | $94K | 49.9% |
| 3 | $144.13 | 3 | $432 | 0.2% |
| Total | $142.36 avg | 1,321 | $188K | 100% |
| Filing → |
| NMRA | SELL | 2026-02-19 | $34K | — | Filing → |
| NMRA | SELL | 2025-02-20 | $23K | — | Filing → |
| MTSR | BUY | 2025-02-03 | $14.2M | — | Filing → |